What's new? Log in Free sign up

Qiagen (QGEN)

Company Profile

Company profile

Ticker

QGEN

Exchange

Website

CEO

Mr. Thierry Bernard

Incorporated

Location

Fiscal year end

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics • Amgen • Gilead Sciences • Biogen • Sterling Check • Bio-Techne • Moderna • bluebird bio • Acorda Therapeutics • Saratoga Investment ...

Former names

QIAGEN NV

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

QGEN stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

QIAGEN delivers strong preliminary Q1 2025 results exceeding outlook and raises full-year 2025 adjusted EPS outlook

Disclosure regarding Iran Threat Reduction and Syria Human Rights Act

Annual report (foreign)

28 Mar 25

QIAGEN delivers solid Q4 2024 growth ahead of outlook

QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

WELLINGTON MANAGEMENT GROUP LLP

WELLINGTON MANAGEMENT GROUP LLP

BlackRock, Inc.

BlackRock, Inc.

Notice of proposed sale of securities

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

Notice of proposed sale of securities

Financial summary

Financial statements Chart QGEN financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Qiagen earnings reports.

Institutional ownership, Q4 2024

QGEN institutional ownership history Ownership history

66.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	310	323	-4.0%
Opened positions	51	54	-5.6%
Closed positions	64	32	+100.0%
Increased positions	110	124	-11.3%
Reduced positions	104	107	-2.8%

13F shares	Current	Prev Q	Change
Total value	5.90 tn	6.32 tn	-6.7%
Total shares	142.79 mm	150.27 mm	-5.0%
Total puts	947.84 k	852.64 k	+11.2%
Total calls	1.55 mm	1.41 mm	+10.5%
Total put/call ratio	0.6	0.6	+0.6%

Largest owners	Shares	Value	Change
Massachusetts Financial Services	25.32 mm	$1.13 tn	+9.5%
Wellington Management	21.78 mm	$970.53 bn	+2.5%
Vanguard	8.88 mm	$397.94 bn	+0.9%
BlackRock	5.61 mm	$249.95 bn	+3.0%
Amundi	5.05 mm	$228.65 bn	-13.7%
Nuance Investments	4.15 mm	$184.58 bn	-7.7%
Norges Bank	4.07 mm	$181.53 bn	NEW
Earnest Partners	4.00 mm	$178.23 bn	+1.6%
BAC Bank of America	3.72 mm	$165.57 bn	-12.9%
MS Morgan Stanley	3.17 mm	$141.33 bn	-1.9%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	4.07 mm	+4.07 mm	NEW
Massachusetts Financial Services	25.32 mm	+2.20 mm	+9.5%
SEIC SEI Investments	11.50 k	-1.67 mm	-99.3%
Millennium Management	0.00	-1.32 mm	EXIT
Southpoint Capital Advisors	0.00	-1.30 mm	EXIT
Citadel Advisors	830.58 k	-1.28 mm	-60.7%
Caisse Des Depots Et Consignations	1.25 mm	+1.25 mm	NEW
JPM JPMorgan Chase & Co.	420.49 k	-1.18 mm	-73.8%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	3.00 mm	-1.15 mm	-27.8%
Amundi	5.05 mm	-799.26 k	-13.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

QIAGEN To Acquire GENOOX For $70M

Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseasesStrengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast

Qiagen FY2025 Reaffirms EPS Of $2.35 CER Vs $2.49 Est

Qiagen (NYSE:QGEN) FY2025 expected to be more than $2.35 vs $2.49 Est..

Qiagen Q1 Adj. EPS $0.55 Misses $0.56 Estimate, Sales $483.00M Miss $507.25M Estimate

Qiagen (NYSE:QGEN) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.56 by 1.79 percent. This is a 17.02 percent increase over earnings of $0.47 per share from the same

Earnings Scheduled For May 7, 2025

QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control

Press releases

From Benzinga Pro

QIAGEN announces plans for transition in leadership of Supervisory Board

Supervisory Board intends to elect Stephen H. Rusckowski as Chairman following Annual General Meeting on June 26, 2025 Lawrence A. Rosen will not stand for re-election and will step down as Chairman and Supervisory

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

Q1 2025 results confirm preliminary announcement: Net sales of $483 million (+5% actual rates, +7% constant exchange rates, CER); adjusted diluted EPS of $0.55 Net sales growth of +7% CER ahead of outlook for about

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board will propose the initiation of an annual cash dividend under an amended dividend policy to QIAGEN's shareholders at the

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.